Docetaxel Injection, Solution, Concentrate
Product Images NDC 0143-9204

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0143-9204). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Docetaxel Anhydrous Structure (Docetaxel Injection Usp 1)

Chemical structure diagram of the active ingredient Docetaxel, showing its molecular framework including multiple rings, hydroxyl groups, and side chains.*

FDA Label Image

Figure 9 (Docetaxel Injection Usp 10)

A survival probability graph depicting two groups labeled TPF and PF over survival time in months. The y-axis indicates survival probability (%) from 0 to 100, and the x-axis shows survival time ranging from 0 to 72 months. The solid line (TPF) consistently shows higher survival probability compared to the dashed line (PF) throughout the time span.*

FDA Label Image

Figure 10 (Docetaxel Injection Usp 11)

A survival probability Kaplan-Meier curve comparing TPF and PF treatment groups over 72 months of survival time in months. The chart shows percentage survival probability on the Y-axis and time on the X-axis, with data points and risk table for patient numbers at intervals.*

FDA Label Image

20 mg/ 1ml Vial Label (Docetaxel Injection Usp 12)

Label for Docetaxel Injection, USP 20 mg/mL solution concentrate for intravenous infusion by Hikma Pharmaceuticals USA Inc. The label states it is a one-vial formulation for single use, highlights caution as a cytotoxic agent, and includes storage instructions and blank spaces for lot and expiration dates.*

FDA Label Image

80 mg/ 4 mL Vial Label (Docetaxel Injection Usp 13)

Docetaxel Injection, USP 80 mg per 4 mL (20 mg/mL) injection concentrate vial label. The label states it is for intravenous infusion only, with a caution that it is a cytotoxic agent. Manufactured by Hikma Pharmaceuticals USA Inc., the label includes storage and handling instructions and identifies it as a one-vial formulation.*

FDA Label Image

Thymoorgan Design 1 (Docetaxel Injection Usp 14)

A product label for Docetaxel injection, solution, concentrate, 20 mg/mL by Hikma Pharmaceuticals USA Inc. The label shows a two-dimensional barcode and includes standardized data fields for GTIN, serial number (SN), expiration date (EXP), and lot number (LOT). Specific numeric values and dates are placeholder text.*

FDA Label Image

Figure 1 (Docetaxel Injection Usp 2)

A survival curve chart showing Disease-Free Survival (DFS) Probability (%) on the vertical axis and Disease-Free Survival Time (months) on the horizontal axis. The chart compares two treatment groups labeled TAC and FAC, depicting DFS probabilities over a period of about 66 months.*

FDA Label Image

Figure 2 (Docetaxel Injection Usp 3)

A Kaplan-Meier survival curve chart displaying survival probability (%) over time in months. Two curves are shown, labeled TAC and FAC, representing different treatment groups. The graph tracks patient survival probabilities up to 66 months.*

FDA Label Image

Figure 3 (Docetaxel Injection Usp 4)

A survival curve chart depicting cumulative probability of overall survival over survival time in months. Two groups are compared: T75 (solid line) and BSC (dashed line). The chart includes a statistical log-rank p-value of 0.010 indicating significance between groups.*

FDA Label Image

Figure 4 (Docetaxel Injection Usp 5)

Kaplan-Meier survival curve chart showing cumulative probability versus survival time in months, comparing two groups labeled T75 and V/I with overall survival log-rank p-value 0.13. The chart depicts overall survival probabilities over time.*

FDA Label Image

Figure 5 (Docetaxel Injection Usp 6)

A survival probability curve graph depicting survival time in months on the x-axis and survival probability on the y-axis. Two lines represent different groups labeled T75 q3w and M q3w, showing changes in survival probability over a 30-month period.*

FDA Label Image

Figure 6 (Docetaxel Injection Usp 7)

A Kaplan-Meier survival curve showing probability (%) over time (months) for two groups labeled TCF and CF. The graph plots survival probability decreasing over a 24-month period, with TCF generally showing higher survival probabilities than CF throughout the timeline.*

FDA Label Image

Figure 7 (Docetaxel Injection Usp 8)

A survival curve chart comparing survival probabilities over time (months) between two groups labeled TCF and CF. The chart's y-axis represents survival probability (%) from 0 to 100, and the x-axis shows survival time in months from 0 to 36. The TCF group is shown with a solid line, and the CF group with a dotted line.*

FDA Label Image

Figure 8 (Docetaxel Injection Usp 9)

A Kaplan-Meier survival curve chart displaying progression-free survival probability (%) on the y-axis and progression-free survival time in months on the x-axis. Two curves are shown: one solid labeled TPF and one dotted labeled PF, illustrating differences in survival outcomes over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.